Braf Pten Mouse

The two alterations act through complementary cancer-related pathways. Oncogenic BRAF activates MAPK signaling, while PTEN loss weakens regulation of the PI3K-AKT pathway. Studying both changes together allows researchers to examine how simultaneous pathway activation and tumor-suppressor loss promote melanoma initiation and progression more effectively than either alteration considered alone.

Cre recombinase controls where, and in some designs when, the genetic alterations become active. Tissue-specific Cre can target melanocytes, whereas inducible Cre provides conditional activation or deletion. This arrangement enables investigators to combine a conditional BRAF mutation with deletion of floxed Pten alleles in a defined biological setting rather than altering every cell.

The model links two major signaling consequences to the same tumor outcome: BRAF V600E-associated MAPK activation and impaired PTEN-dependent control of PI3K-AKT signaling. This combination helps investigators study pathway cooperation during tumor development and provides a framework for evaluating therapies directed at BRAF, MEK, PI3K, or related signaling components.

Because tumor development occurs in an immunocompetent setting, researchers can investigate cancer biology alongside immune responses rather than studying tumor cells in isolation. This is particularly useful for examining how melanoma progression and treatment interact with the host immune environment, expanding analysis beyond tumor growth alone.

A typical design combines a conditional oncogenic Braf allele, such as BRAF V600E, with floxed Pten alleles and a Cre recombinase system directed toward melanocytes. Cre activation produces the intended genetic changes in the selected cellular context. This workflow creates a defined model for examining tumor initiation and subsequent progression.

These mice support studies of tumor biology, including how melanoma begins and advances after cooperating genetic changes are introduced. Their defined genetic context allows researchers to connect pathway alterations with tumor initiation and progression, while the immunocompetent background also supports investigation of immune responses associated with those processes.

Researchers can use the models to test therapeutic strategies aimed at BRAF, MEK, PI3K, or related pathways and then examine how tumors respond. Because the model incorporates both MAPK activation and impaired PI3K-AKT regulation, it provides a context for investigating treatment resistance that may arise when cooperating signaling abnormalities influence therapeutic outcomes.